Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background Erectile dysfunction (ED) occurs more frequently and causes a worse response to the first-line therapies in diabetics compared with non-diabetic men. Corpus cavernosum vascular dysfunction plays a pivotal role in the occurrence of diabetes mellitus ED (DMED). The aim of this study was to investigate the protective effects of glucagon-like peptide-1 (GLP-1) analog liraglutide on ED and explore the underlying mechanisms in vivo and vitro. Methods Type 1 diabetes was induced in rats by streptozotocin, and the apomorphine test was for screening the DMED model in diabetic rats. Then they were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12h) for 4 weeks. Erectile function was assessed by cavernous nerve electrostimulation. The corpus cavernosum was used for further study. In vitro, effects of liraglutide were evaluated by primary corpus cavernosum smooth muscle cells (CCSMCs) exposed to low or high glucose (HG)-containing medium with or without liraglutide and GLP-1 receptor (GLP-1R) inhibitor. Western blotting, fluorescent probe, immunohistochemistry and relevant assay kits were performed to measure the levels of target proteins. Results Administration of liraglutide did not significantly affect plasma glucose and body weights in diabetic rats, but improved erectile function, reduced levels of NADPH oxidases and ROS production, downregulated expression of Ras homolog gene family (RhoA) and Rho-associated protein kinase (ROCK) 2 in the DMED group dramatically. The liraglutide treatment promoted autophagy further and restored expression of GLP-1R in the DMED group. Besides, cultured CCSMCs with liraglutide exhibited a lower level of oxidative stress accompanied by inhibition of the RhoA/ROCK pathway and a higher level of autophagy compared with HG treatment. These beneficial effects of liraglutide effectively reversed by GLP-1R inhibitor. Conclusion Liraglutide exerts protective effects on ED associated with the regulation of smooth muscle dysfunction, oxidative stress and autophagy, independently of a glucose- lowering effect. It provides new insight into the extrapancreatic actions of liraglutide and preclinical evidence for a potential treatment for DMED.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 1×
“It has been reported that GLP-1 agonists show cardioprotective and vasodilatory effects (Hattori et al., 2010), such as ameliorating endothelial and vascular dysfunction, protecting against cardiac ischemia and steatosis, relieving atherosclerosis and left ventricular performance after myocardial infarction (Inoue et…”
BackgroundRetractedIDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283 · cited 1×
“It is estimated that more than 300 million will experience diabetes globally by 2025 and 693 million by 2045 (Cho et al., 2018), along with increasing cases of DMED.”
BackgroundOxidative stress and autophagy: The clash between damage and metabolic needs
Filomeni, G., De Zio, D., & Cecconi, F. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.150 · Cited by 2,195 · cited 1×
“Autophagy is a biological process against detrimental conditions such as oxidative stress and nutrient deprivation by recycling damaged organelles and cellular components to maintain cellular homeostasis (Filomeni et al., 2015).”
BackgroundReactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4
Scherz‐Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., & Elazar, Z. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601623 · Cited by 2,101
Shamloul, R., & Ghanem, H. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60520-0 · Cited by 1,091
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Spitzer, M., Basaria, S., Travison, T. G., Davda, M. N., Paley, A., Cohen, B., Mazer, N. A., Knapp, P. E., Hanka, S., Lakshman, K. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00004 · Cited by 163 · cited 1×
“Compared with nondiabetic men, patients with ED are inclined to be refractory to phosphodiesterase type 5 inhibitors, the first-line therapeutic drug for ED currently, due to incompletely understood mechanisms (Spitzer et al., 2012).”
BackgroundGiagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91 · cited 2×
“Liraglutide was added to the medium 60 min before HG treatment, and exendin (9–39) was added 30 min before HG treatment (Shi et al., 2015).”
BackgroundMethodSelf-citation
Cited by
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Bajaj, H. S., Gerstein, H. C., Rao-Melacini, P., Basile, J., Colhoun, H., Conget, I., Cushman, W. C., Dagenais, G. R., Franek, E., Hanefeld, M., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00115-7 · Cited by 56
Role of Glucose-Lowering Medications in Erectile Dysfunction
Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112501 · Cited by 30
“In addition, GLP-1R inhibition abolished the beneficial functions of liraglutide treatment [151].”
BackgroundInfluentialDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Furthermore, GLP-1R may also be found in the corpus cavernosum, supporting the benefits of GLP-1 RAs for erectile function [36].”
Background
Metadata
- Authors
- Yuan, P., Ma, D., Gao, X., Wang, J., Li, R., Liu, Z., Wang, T., Wang, S., Liu, J., & Liu, X.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-12
- Volume
- 11
- Pages
- 1257-1257
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3048623850
- Cited by
- 93
- References
- 10
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus. https://app.cochat.ai/papers/10.3389/fphar.2020.01257
- The paper
- Yuan, P., Ma, D., Gao, X., Wang, J., Li, R., Liu, Z., Wang, T., Wang, S., Liu, J., & Liu, X. (2020). Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.01257
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.